Home » Stocks » ASRT

Assertio Therapeutics, Inc. (ASRT)

Stock Price: $0.640 USD 0.049 (8.37%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $0.640 +0.001 (0.08%) Jan 20, 7:41 AM
Market Cap 68.57M
Revenue (ttm) 135.33M
Net Income (ttm) -196.42M
Shares Out 119.56M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE 5.36
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $0.640
Previous Close $0.590
Change ($) 0.049
Change (%) 8.37%
Day's Open 0.598
Day's Range 0.590 - 0.640
Day's Volume 6,922,843
52-Week Range 0.340 - 1.080

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.

GlobeNewsWire - 3 weeks ago

Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing

GlobeNewsWire - 2 months ago

LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, ...

Seeking Alpha - 2 months ago

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 2 months ago

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the comp...

Seeking Alpha - 5 months ago

Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.

Benzinga - 5 months ago

Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07.

Zacks Investment Research - 5 months ago

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2...

Seeking Alpha - 8 months ago

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 8 months ago

-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt --

Zacks Investment Research - 8 months ago

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 9 months ago

LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash ...

GlobeNewsWire - 10 months ago

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1

GlobeNewsWire - 10 months ago

LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the ...

Seeking Alpha - 10 months ago

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

Seeking Alpha - 11 months ago

Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance

GlobeNewsWire - 11 months ago

Also Announces its Senior Secured Debt Has Been Repaid in Full Also Announces its Senior Secured Debt Has Been Repaid in Full

Zacks Investment Research - 11 months ago

Assertio (ASRT) closed at $1.35 in the latest trading session, marking a -0.74% move from the prior day.

GlobeNewsWire - 11 months ago

Company Intends to Use Cash Proceeds to Retire its Outstanding Debt

Zacks Investment Research - 11 months ago

Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.

Zacks Investment Research - 11 months ago

Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.

Zacks Investment Research - 11 months ago

Is (ASRT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreeme...

Zacks Investment Research - 1 year ago

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
Zacks Investment Research - 1 year ago

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (NASDAQ: ASRT), today announced it has entered into an agreement with Alvogen, a global privatel...

Zacks Investment Research - 1 year ago

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
Seeking Alpha - 1 year ago

Assertio Is Prime For A Valuation Recovery

Seeking Alpha - 1 year ago

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has rec...

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon has been appointed to the Company’s Board of Directors...

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzg...

Zacks Investment Research - 1 year ago

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
Zacks Investment Research - 1 year ago

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
Zacks Investment Research - 1 year ago

Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GuruFocus - 1 year ago

Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of...

Seeking Alpha - 1 year ago

Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

About ASRT

Assertio Holdings operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treating migraine; Zipsor, an NSAID for relief of mild to moderate acute pain; Gralise, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; NUCYNTA ER, an extended-release version of tapentadol for the management of neuropathic pain associated with diabetic peripheral neuropathy; and NUCYNTA IR, an immediate release version... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Nov 5, 1997
CEO
Daniel A. Peisert
Employees
125
Stock Exchange
NASDAQ
Ticker Symbol
ASRT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 0.75, which is an increase of 17.28% from the latest price.

Price Target
$0.75
(17.28% upside)
Analyst Consensus: Buy